Portola Pharmaceuticals to Announce Second Quarter 2013 Financial Results and Host Conference Call on Thursday, August 15, 2013
07 Août 2013 - 10:30PM
Business Wire
Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) will host a
conference call and webcast on Thursday, August 15, at 8:30 a.m.
Eastern Time to discuss its second quarter 2013 financial results
and to provide a general business update. A press release for the
second quarter of 2013 will be released prior to the opening of the
markets on August 15, 2013.
Conference Call Details
To access the live conference call on August 15, 2013 at 8:30
a.m. Eastern Time via phone, please dial (800) 322-2803 from the
United States and Canada or +1(617) 614-4925 internationally. The
participant passcode is 69614971. Please dial in 10 minutes prior
to the start of the call.
To access the live and subsequently archived webcast of the
conference call, go to the Investor Relations section of the
company’s website at http://investors.portola.com. Please connect
to the website at least 15 minutes prior to the call to allow for
any software download that may be necessary.
About Portola Pharmaceuticals
Portola is a biopharmaceutical company focused on the
development and commercialization of novel therapeutics in the
areas of thrombosis (blood clots), other hematologic (blood)
disorders and inflammation for patients who currently have limited
or no approved treatment options.
Portola’s lead compound, betrixaban, is an investigational,
novel, oral once-daily inhibitor of Factor Xa in Phase 3
development for extended-duration prophylaxis (preventive
treatment) of a form of thrombosis known as venous thromboembolism
(VTE) in acute medically ill patients. Currently, there is no
anticoagulant approved for extended-duration VTE prophylaxis in
this population.
Portola’s second lead development candidate, andexanet alfa
(proposed International Nonproprietary Name), is a recombinant
protein designed to reverse the anticoagulant activity in patients
treated with a Factor Xa inhibitor who suffer an uncontrolled
bleeding episode or require emergency surgery. Portola has entered
into collaboration agreements with Bristol-Myers Squibb Company and
Pfizer Inc., with Bayer Pharma AG and Janssen Pharmaceuticals,
Inc., and with Daiichi Sankyo to study andexanet alfa with Eliquis®
(apixaban), XARELTO® (rivaroxaban) and edoxaban, respectively, in
Portola’s Phase 2 studies. Portola retains full, worldwide
commercial rights with respect to andexanet alfa.
Portola’s third product candidate, PRT2070, is an orally
available kinase inhibitor being developed for hematologic cancers
and inflammatory disorders. PRT2070 inhibits spleen tyrosine kinase
(Syk) and janus kinases (JAK), enzymes that regulate important
signaling pathways. Portola plans to file an Investigational New
Drug (IND) application and initiate a Phase 1/2 clinical study of
PRT2070 in 2013 in patients with B-cell hematologic cancers who
have failed or relapsed on existing marketed therapies or products
in development, including patients with identified mutations.
Portola’s fourth program, PRT2607 and other highly selective Syk
inhibitors, is partnered with Biogen Idec Inc.
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
